DOCSLIB.ORG

Terbinafine and Itraconazole)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Terbinafine and Itraconazole) Client HMSA: PQSR 2009 Measure Title HEPATIC ENZYME MONITORING FOR PERSONS USING ANTIMYCOTIC PHARMACOTHERAPY (TERBINAFINE AND ITRACONAZOLE) Disease State Liver Disease Indicator Classification Medication Monitoring Strength of B Recommendation Organizations American Academy of Family Physicians Providing Recommendation Clinical Intent To ensure that all eligible members who have a new prescription for certain antimycotic pharmacotherapy receive the necessary pretreatment evaluation. Physician Specialties Refer to PQSR 2009 Clinical Measures by Specialty. (suggested) Background Disease Burden • Estimates for the prevalence of onychomycosis in North American Countries range from 8‐14%.[1‐3] However, other cross‐sectional studies show that this rate may vary by age and occupation.[4, 5] • Risk factors for onychomycosis include exposure to family members with the disease, immunodeficiency, diabetes, psoriasis, tinea pedis, frequent swimming, and older age.[6] • Generally, affected nails are visibly abnormal, causing embarrassment and negative effects on patients’ personal, social and occupational functioning.[7‐9] Reason for Indicated Intervention or Treatment • When compared to older antifungal medications griseofulvin, terbinafine and itraconazole have higher cure rates in randomized controlled trials.[10‐12] • While fluconazole is also found to be effective in patients with onychomycosis, it is not as effective in terms of cost or cure as itraconazole and terbinafine.[13] Evidence Supporting Intervention or Treatment • Terbinafine’s hepatotoxic effects are acknowledged in the drug’s product monographs,[14] and have been reported multiple times in the literature,[15‐28] and Itraconazole‐induced hepatoxicity has also been well‐documented.[29‐34] • The FDA has issued a public health advisory about terbinafine and itraconazole citing the association between congestive heart failure and hepatic adverse events with the administration of these therapies.[35] • There are at least 16 case reports in the English literature describing the development of necro‐inflammatory and cholestatic hepatotoxicity with terbinafine use [15‐27], and at least 5 case reports from non‐English literature.[28, 36‐39] Similarly, multiple case reports have described hepatotoxicity associated with itraconazole use.[29, 30, 32, 33] • A 2007 meta analysis of 122 studies, involving a total of 19,298 patients reported that pooled risks (95% confidence intervals) of oral antifungal treatment discontinuation resulting from adverse reactions for continuous therapy were 3.44% (95% confidence interval [CI], 2.28%‐4.61%) for terbinafine 250 mg/day; 1.96% (95% CI, 0.35%‐3.57%) for itraconazole 100 mg/day; 4.21% (95% CI, 2.33%‐6.09%) for itraconazole 200 mg/day; and 1.51% (95% CI, 0%‐4.01%) for fluconazole 50 mg/day. For intermittent therapy, the pooled risks were as follows: pulse terbinafine: 2.09% (95% CI, 0%‐4.42%); pulse itraconazole: 2.58% (95% CI, 1.15%‐4.01%); intermittent fluconazole 150 mg/week: 1.98% (95% CI, 0.05%‐3.92%); and intermittent fluconazole 300 to 450 mg/week: 5.76% (95% CI, 2.42%‐9.10%). • According to this meta‐analysis, the risk of liver injury requiring termination of treatment ranged from 0.11% (continuous itraconazole 100 mg/day) to 1.22% (continuous fluconazole 50 mg/day). The risk of having asymptomatic elevation of serum transaminase but not requiring treatment discontinuation was less than 2.0% for all treatment regimens evaluated.[40] • The crude incidence rate of acute liver injury associated with itraconazole use is approximately 1:10,000.[31] • A cohort study of 19,488 patients showed that patients taking itraconazole had a relative risk of 17.7 (95% confidence interval 2.6, 72.6) of developing acute liver injury when compared to the risk among nonusers.[31] Clinical • For continuous treatment, the American Academy of Family Recommendations Physicians recommends checking baseline liver enzyme levels before starting terbinafine or itraconazole, and then testing every four to six weeks during treatment. No testing is suggested for pulse therapy.[41] Source Health Benchmarks, Inc. Denominator Denominator Continuously enrolled members who filled at least 1 prescription for oral Definition treatment with Lamisil (terbinafine) or Sporanox (itraconazole) during the first 358 days of the measurement year. Denominator Exclusion Denominator Members who filled a prescription for oral treatment with Lamisil Exclusion Definition (terbinafine) or Sporanox (itraconazole) during the 1‐365 days prior to the index date. Numerator Numerator Members who have had appropriate monitoring lab work (i.e. hepatic Definition function panel, general health panel, AST, ALT) completed during the 90 days prior through 7 days after the index date. Physician Attribution Physician Score only the physician who prescribed the member Lamisil Attribution (terbinafine) or Sporanox (itraconazole) on the index date (i.e. Description denominator criterion A). References 1. Novartis, Lamisil Prescribing Information. 2005, Novartis Pharmaceuticals Corporation: East Hanover, NJ. 2. FDA, THE SAFETY OF SPORANOX® CAPSULES AND LAMISIL® TABLETS FOR THE TREATMENT OF ONYCHOMYCOSIS, in Public Health Advisory. 2001, Food and Drug Administration: Atlanta, GA. 3. Garcia Rodriguez, L.A., et al., A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol, 1999. 48(6): p. 847‐52. 4. Health_Canada, Important Drug Warning ‐ Lamisil ‐ (terbinafine HCL) ‐ Novartis. 2001, Health Canada. 5. Fernandes, N.F., S.A. Geller, and T.L. Fong, Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol, 1998. 93(3): p. 459‐60. 6. Gupta, A.K., et al., Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol, 1998. 23(2): p. 64‐7. 7. van 't Wout, J.W., et al., Terbinafine‐associated hepatic injury. J Hepatol, 1994. 21(1): p. 115‐7. 8. Lazaros, G.A., et al., Terbinafine‐induced cholestatic liver disease. J Hepatol, 1996. 24(6): p. 753‐6. 9. Mallat, A., et al., Terbinafine‐induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci, 1997. 42(7): p. 1486‐8. 10. Ajit, C., et al., Terbinafine‐associated hepatotoxicity. Am J Med Sci, 2003. 325(5): p. 292‐5. 11. Agarwal, K., D.M. Manas, and M. Hudson, Terbinafine and fulminant hepatic failure. N Engl J Med, 1999. 340(16): p. 1292‐ 3. 12. Lowe, G., C. Green, and P. Jennings, Hepatitis associated with terbinafine treatment. Bmj, 1993. 306(6872): p. 248. 13. Zapata Garrido, A.J., A.C. Romo, and F.B. Padilla, Terbinafine hepatotoxicity. A case report and review of literature. Ann Hepatol, 2003. 2(1): p. 47‐51. 14. Dwyer, C.M., M.I. White, and T.S. Sinclair, Cholestatic jaundice due to terbinafine. Br J Dermatol, 1997. 136(6): p. 976‐7. 15. Chambers, W.M., et al., Terbinafine‐induced hepatic dysfunction. Eur J Gastroenterol Hepatol, 2001. 13(9): p. 1115‐8. 16. Hall, M., et al., Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol, 1997. 133(10): p. 1213‐9. 17. Anania, F.A. and L. Rabin, Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Am J Med, 2002. 112(9): p. 741‐2. 18. Burstein, Z., et al., [Colestasic toxic hepatitis caused by terbinafine: case report]. Rev Gastroenterol Peru, 2004. 24(4): p. 357‐62. 19. Lavrijsen, A.P., et al., [Liver damage during administration of itraconazole (Trisporal)]. Ned Tijdschr Geneeskd, 1993. 137(1): p. 38‐41. 20. Lavrijsen, A.P., et al., Hepatic injury associated with itraconazole. Lancet, 1992. 340(8813): p. 251‐2. 21. Gallardo‐Quesada, S., J. Luelmo‐Aguilar, and C. Guanyabens‐ Calvet, Hepatotoxicity associated with itraconazole. Int J Dermatol, 1995. 34(8): p. 589. 22. Adriaenssens, B., et al., Hepatotoxicity related to itraconazole: report of three cases. Acta Clin Belg, 2001. 56(6): p. 364‐9. 23. Somchit, N., et al., Hepatotoxicity induced by antifungal drugs itraconazole and fluconazole in rats: a comparative in vivo study. Hum Exp Toxicol, 2004. 23(11): p. 519‐25. 24. Boldewijn, O.Y., et al., [Hepatitis attributed to the use of terbinafine]. Ned Tijdschr Geneeskd, 1996. 140(12): p. 669‐72. 25. Ihre‐Lundgren, C., J. Frisell, and U. Bergman, [A patient treated with terbinafine. Intrahepatic biliary stasis is a severe adverse effect]. Lakartidningen, 1995. 92(11): p. 1112‐3. 26. Shiloah, E., M. Horowiz, and E. Zecler, [Terbinafine‐induced cholestatic liver injury]. Harefuah, 1997. 133(1‐2): p. 11‐2, 80‐1. 27. Vivas, S., et al., [Acute hepatitis associated with terbinafine]. Gastroenterol Hepatol, 1997. 20(9): p. 456‐8. 28. Girois, S.B., et al., Adverse effects of antifungal therapies in invasive fungal infections: review and meta‐analysis. Eur J Clin Microbiol Infect Dis, 2005. 24(2): p. 119‐30. 29. Rodgers, P. and M. Bassler, Treating onychomycosis. Am Fam Physician, 2001. 63(4): p. 663‐72, 677‐8. © 2008 Health Benchmarks and HMSA. All rights reserved. .
Load more

Recommended publications
  • Terbinafine-Induced Taste Impairment - Report of Two Cases Rajesh Sinha, Pallavi Sharma, Pramod Kumar, Vaibhav Kuchhal*
    Journal of Pakistan Association of Dermatologists 2012; 22 (4):363-365. Case Report Terbinafine-induced taste impairment - report of two cases Rajesh Sinha, Pallavi Sharma, Pramod Kumar, Vaibhav Kuchhal* Department of Skin &V.D., Government Medical College, Haldwani 263139, Uttarakhand, India *Department of E.N.T., Government Medical College, Haldwani 263139, Uttarakhand, India Abstract Terbinafine is an oral antimycotic agent that belongs to the allylamine class. It was introduced in 1991 and is being widely used, both topically and systemically, to treat fungal infections. Nowadays oral terbinafine has become a commonly prescribed drug to treat finger- and toenail fungal infections because of relatively short duration of treatment compared to other oral antifungals like griseofulvin and fluconazole. The common side effects of this drug include nausea, abdominal pain, elevated transaminases and allergic reactions. Loss of taste sensation is a rare side effect occurring in patient taking oral form of this drug. PubMed search showed that very few cases of terbinafine- induced taste loss have been reported worldwide. We report a case series of two patients who complained of taste loss after taking terbinafine. Key words Terbinafine, ageusia. Introduction terbinafine that occurs in 0.6% to 2.8% of patients taking the drug. A low BMI, ageing Terbinafine is a widely prescribed oral and history of taste loss are considered risk antifungal agent. Its mode of action is by factors for developing taste loss due to inhibiting squalene epoxidase which converts terbinafine. squalene to lanosterol. With a decrease in lanosterol production, ergosterol production is Case report 1 also diminished, affecting fungal cell membrane synthesis and function.
    [Show full text]
  • Long-Term Effectiveness of Treatment with Terbinafine Vs Itraconazole in Onychomycosis a 5-Year Blinded Prospective Follow-Up Study
    STUDY Long-term Effectiveness of Treatment With Terbinafine vs Itraconazole in Onychomycosis A 5-Year Blinded Prospective Follow-up Study Ba´rður Sigurgeirsson, MD, PhD; Jo´n H. O´ lafsson, MD, PhD; Jo´n þ. Steinsson, MD Carle Paul, MD; Stephan Billstein, MD; E. Glyn V. Evans, PhD Objective: To examine long-term cure and relapse rates microscopy and culture at the end of follow-up and no re- after treatment with continuous terbinafine and inter- quirement of second intervention treatment. Secondary ef- mittent itraconazole in onychomycosis. ficacy criteria included clinical cure without second inter- vention treatment and mycological and clinical relapse rates. Design: Long-term prospective follow-up study. Results: Median duration of follow-up was 54 months. Setting: Three centers in Iceland. At the end of the study, mycological cure without second intervention treatment was found in 34 (46%) of the 74 Subjects: The study population comprised 151 pa- terbinafine-treated subjects and 10 (13%) of the 77 itra- tients aged 18 to 75 years with a clinical and mycologi- conazole-treated subjects (PϽ.001). Mycological and clini- cal diagnosis of dermatophyte toenail onychomycosis. cal relapse rates were significantly higher in itraconazole- vs terbinafine-treated patients (53% vs 23% and 48% vs Interventions: In a double-blind, double-dummy study, 21%, respectively). Of the 72 patients who received sub- patients were randomized to receive either terbinafine (250 sequent terbinafine treatment, 63 (88%) achieved myco- mg/d) for 12 or 16 weeks or itraconazole (400 mg/d) for logical cure and 55 (76%) achieved clinical cure. 1 week in every 4 for 12 or 16 weeks (first intervention).
    [Show full text]
  • Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut
    ■ CLINICAL REVIEW Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut Tinea versicolor (pityriasis versicolor) is a common imidazole, has been used for years both orally and top­ superficial fungal infection of the stratum corneum. ically with great success, although it has not been Caused by the fungus Malassezia furfur, this chronical­ approved by the Food and Drug Administration for the ly recurring disease is most prevalent in the tropics but indication of tinea versicolor. Newer derivatives, such is also common in temperate climates. Treatments are as fluconazole and itraconazole, have recently been available and cure rates are high, although recurrences introduced. Side effects associated with these triazoles are common. Traditional topical agents such as seleni­ tend to be minor and low in incidence. Except for keto­ um sulfide are effective, but recurrence following treat­ conazole, oral antifungals carry a low risk of hepato- ment with these agents is likely and often rapid. toxicity. Currently, therapeutic interest is focused on synthetic Key Words: Tinea versicolor; pityriasis versicolor; anti­ “-azole” antifungal drugs, which interfere with the sterol fungal agents. metabolism of the infectious agent. Ketoconazole, an (J Fam Pract 1996; 43:127-132) ormal skin flora includes two morpho­ than formerly thought. In one study, children under logically discrete lipophilic yeasts: a age 14 represented nearly 5% of confirmed cases spherical form, Pityrosporum orbicu- of the disease.3 In many of these cases, the face lare, and an ovoid form, Pityrosporum was involved, a rare manifestation of the disease in ovale. Whether these are separate enti­ adults.1 The condition is most prevalent in tropical tiesN or different morphologic forms in the cell and semitropical areas, where up to 40% of some cycle of the same organism remains unclear.: In the populations are affected.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Nails: Tales, Fails and What Prevails in Treating Onychomycosis
    J. Hibler, D.O. OhioHealth - O’Bleness Memorial Hospital, Athens, Ohio AOCD Annual Conference Orlando, Florida 10.18.15 A) Onychodystrophy B) Onychogryphosis C)“Question Onychomycosis dogma” – Michael Conroy, MD D) All the above E) None of the above Nail development begins at 8-10 weeks EGA Complete by 5th month Keratinization ~11 weeks No granular layer Nail plate growth: Fingernails 3 mm/month, toenails 1 mm/month Faster in summer or winter? Summer! Index finger or 5th digit nail grows faster? Index finger! Faster growth to middle or lateral edge of each nail? Lateral! Elkonyxis Mee’s lines Aka leukonychia striata Arsenic poisoning Trauma Medications Illness Psoriasis flare Muerhrcke’s bands Hypoalbuminemia Chemotherapy Half & half nails Aka Lindsay’s nails Chronic renal disease Terry’s nails Liver failure, Cirrhosis Malnutrition Diabetes Cardiovascular disease True or False: Onychomycosis = Tinea Unguium? FALSE. Onychomycosis: A fungal disease of the nails (all causes) Dermatophytes, yeasts, molds Tinea unguium: A fungal disease of nail caused by dermatophyte fungi Onychodystrophy ≠ onychomycosis Accounts for up to 50% of all nail disorders Prevalence; 14-28% of > 60 year-olds Variety of subtypes; know them! Sequelae What is the most common cause of onychomycosis? A) Epidermophyton floccosum B) Microsporum spp C) Trichophyton mentagrophytes D) Trichophyton rubrum -Account for ~90% of infections Dermatophytes Trichophyton rubrum Trichophyton mentagrophytes Trichophyton tonsurans, Microsporum canis, Epidermophyton floccosum Nondermatophyte molds Acremonium spp, Fusarium spp Scopulariopsis spp, Sytalidium spp, Aspergillus spp Yeast Candida parapsilosis Candida albicans Candida spp Distal/lateral subungal Proximal subungual onychomycosis onychomycosis (DLSO) (PSO) Most common; T. rubrum Often in immunosuppressed patients T.
    [Show full text]
  • Treatment of Interdigital Tinea Pedis with 25% and 50% Tea Tree Oil Solution: a Randomized, Placebo-Controlled, Blinded Study
    Australasian Journal of Dermatology (2002) 43, 175–178 RESEARCH REPORT Treatment of interdigital tinea pedis with 25% and 50% tea tree oil solution: A randomized, placebo-controlled, blinded study Andrew C Satchell,1 Anne Saurajen,1 Craig Bell2 and Ross StC Barnetson1 1Department of Dermatology, Royal Prince Alfred Hospital, Camperdown and 2Australian Tea Tree Oil Research Institute, Southern Cross University, Lismore, New South Wales, Australia and Epidermophyton floccosum, and appears to be related 2 SUMMARY to occlusive footwear. Tinea pedis occurs as one of four clinical variants: intertriginous, papulosquamous, vesicular Tea tree oil has been shown to have activity against and acute ulcerative.3 Chronic, intertriginous tinea pedis is dermatophytes in vitro. We have conducted a random- characterized by a scaling and fissuring of the lateral toe ized, controlled, double-blinded study to determine the webs caused by dermatophyte invasion of the stratum efficacy and safety of 25% and 50% tea tree oil in corneum; macerated, erosive infections may follow as a result the treatment of interdigital tinea pedis. One hundred of secondary overgrowth of commensal bacteria, including and fifty-eight patients with tinea pedis clinically and Micrococcaceae (usually staphylococci), aerobic coryneforms microscopy suggestive of a dermatophyte infection and Gram-negative organisms.4 Microscopy and culture of were randomized to receive either placebo, 25% or 50% skin scrapings are used to identify the relevant organism. tea tree oil solution. Patients applied the solution twice The treatment of intertiginous tinea pedis includes daily to affected areas for 4 weeks and were reviewed measures aimed at reducing hyperhidrosis, such as talcum after 2 and 4 weeks of treatment.
    [Show full text]
  • Terbinafine (TER-Bin-A-Feen)/ Urea (Ure-EE-A)/Thymol
    Amphotericin B (am-foe-TER-i-sin B)/ Terbinafine (TER-bin-a-feen)/ Urea (ure-EE-a)/Thymol Treats a fungus infection on your skin, including tinea pedis (“athlete’s foot”), Treats certain skin and nail conditions. How to Use This Medicine: Cream • Your doctor will tell you how much of this medicine to apply and how often. Do not use more medicine or apply it more often than your doctor tells you to. • Follow the instructions on the medicine label if you are using this medicine without a prescription. • Use this medicine only on your skin or nails. Rinse it off right away if it gets on a cut or scrape. Do not get the medicine in your eyes, nose, or mouth. • Before using this medicine, use soap and water to wash the skin where you will use the medicine. Dry your skin with a clean towel. • Put a thin layer of the cream over the infected area and rub it in gently. • Do not cover the treated area with a bandage unless directed by your doctor. • When applying topical preparations to nails, let drug dry uncovered, unless otherwise directed by your doctor. • Take all of the medicine in your prescription to clear up your infection, even if you feel better after the first few doses. • Wash your hands with soap and water before and after you use this medicine. • Do not apply cosmetics, or other skin products to treated skin areas when using topical preparations. Avoid drug contact with eyes, lips, or mucous membranes. Possible Side Effects While Using This Medicine: Call your doctor right away if you notice any of these side effects: • Itching, rash, swelling, blisters, or redness that were not there before you used this medicine • Drug may cause sun sensitivity.
    [Show full text]
  • Fluconazole, Griseofulvin, Itraconazole, Terbinafine) in Current Epidemic of Altered Dermatophytosis in India: a Randomized Pragmatic Trial
    medRxiv preprint doi: https://doi.org/10.1101/19003541; this version posted August 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Title Effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole, terbinafine) in current epidemic of altered dermatophytosis in India: A randomized pragmatic trial Authors 1. Sanjay Singh, MD, DNB, PhD 2. Usha Chandra, MD 3. Priyanka Verma, MD 4. Vinayak N Anchan, MBBS 5. Ragini Tilaka, MD Departments of Dermatology and Venereology, and aMicrobiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India Sources of support: Banaras Hindu University Address for correspondence: Dr Sanjay Singh, Professor and Head, Department of Dermatology and Venereology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. Email: [email protected] One Sentence Summary: Effectiveness of all four antifungals has declined, with itraconazole being the most effective currently in dermatophytosis in India. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/19003541; this version posted August 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 2 Abstract Background: Dermatophyte infections have undergone unprecedented changes in India in recent past.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Comparative Evaluation of the Efficacy and Safety of Two Doses Of
    Original article Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day)1) in the treatment of cutaneous or lymphocutaneous sporotrichosis Vergleichende Bewertung der Wirksamkeit und Sicherheit zweier Terbinafin-Dosierungen (500 und 1000 mg/Tag) in der Therapie der kutanen und lymphokutanen Sporotrichose S. W. Chapman,1 P. Pappas,2 C. Kauffmann,3 E. B. Smith,4 R. Dietze,5 N. Tiraboschi-Foss,6 A. Restrepo,7 A. B. Bustamante,8 C. Opper,2,9 S. Emady-Azar10 and R. Bakshi10 1University of Mississippi Medical Center, Jackson, MS, USA, 2University of Alabama, Birmingham, AL, USA, 3University of Michigan Medical School and Veteran Affairs Medical Centre, Ann Arbour, MI, USA, 4University of New Mexico, Albuquerque, NM, USA, 5Nu´cleo de Doenc¸as Infecciosas, Universidade Ferderal do Espirito Santo, Vitoria, Brazil, 6University of Sa˜o Paulo, Ribeira˜o Preto, Sa˜o Paulo, Brazil, 7National University of Columbia, Medellin, Columbia, 8Instituto de Medicina Tropical ‘Alexander von Humboldt’, Universidad Peruana Cayetano Heredia, Lima, Peru, 9Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA and 10Novartis Pharma AG, Basel, Switzerland Summary The aim of this study was to evaluate the safety and efficacy of oral terbinafine (500 and 1000 mg day)1) in the treatment of cutaneous or lymphocutaneous sporotrichosis. A culture for Sporothrix schenckii was required for inclusion into this multicentre, randomized, double-blind, parallel-group study. Patients received either 250 mg b.i.d. or 500 mg b.i.d. oral terbinafine for up to a maximum of 24 weeks and were assessed up to 24 weeks post-treatment.
    [Show full text]
  • Antifungal Drugs to Address Unmet Medical Need
    Antifungal Drugs to Address Unmet Medical Need John H. Rex, MD Chief Medical Officer, F2G Limited 4 Aug 2020 FDA Workshop 2020-08-04 F2G comments at FDA Antifungal workshop 1 Background on Olorofim • Olorofim • Is a novel mechanism candidate antifungal drug1 • It inhibits DHODH (pyrimidine biosynthesis pathway) • It shows broad microbiologic activity vs. mould fungi • Low MICs vs. Aspergillus spp., Lomentospora prolificans, Scedosporium spp., Fusarium spp., Coccidioides spp., and others • Fungicidal effects in vitro (Aspergillus) and in vivo (Coccidioides)2,3 • Dosed by mouth (30-mg tablet), it has FDA Breakthrough Therapy Designation based on • “preliminary clinical evidence indicating that it may … • demonstrate substantial improvement over existing therapies … • on one or more clinically significant endpoints.” • Now in an open-label Phase 2 study (NCT03583164) of mould IFD4 in patients with limited treatment options 1. Oliver JD et al. (2016). "F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase." PNAS USA 113: 12809-14. 2. du Pre, S., et al. (2018). "Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus." AAC 62(8): e00231-18. 3. Wiederhold, N. P., et al. (2018). "The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis." AAC 62(9): e00999-18. 4. IFD = Invasive Fungal Disease 2020-08-04 F2G comments at FDA Antifungal workshop 2 Endpoints: A trial design problem • Day 42 All-Cause Mortality
    [Show full text]
  • The Selection and Use of Essential Medicines
    WHO Technical Report Series 958 THE SELECTION AND USE OF ESSENTIAL MEDICINES This report presents the recommendations of the WHO Expert THE SELECTION AND USE Committee responsible for updating the WHO Model List of Essential Medicines. The fi rst part contains a review of the OF ESSENTIAL MEDICINES report of the meeting of the Expert Subcommittee on the Selection and Use of Essential Medicines, held in October 2008. It also provides details of new applications for paediatric medicines and summarizes the Committee’s considerations and justifi cations for additions and changes to the Model List, including its recommendations. Part Two of the publication is the report of the second meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. Annexes include the revised version of the WHO Model List of Essential Medicines (the 16th) and the revised version of the WHO Model List of Report of the WHO Expert Committee, 2009 Essential Medicines for Children (the 2nd). In addition there is a list of all the items on the Model List sorted according to their (including the 16th WHO Model List of Essential Medicines Anatomical Therapeutic Chemical (ATC) classifi cation codes. and the 2nd WHO Model List of Essential Medicines for Children) WHO Technical Report Series — 958 WHO Technical ISBN 978-92-4-120958-8 Geneva TTRS958cover.inddRS958cover.indd 1 110.06.100.06.10 008:328:32 The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for SELECTED WHO PUBLICATIONS OF RELATED INTEREST international health matters and public health.
    [Show full text]